Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01875250 · ClinicalTrials.gov registry record · Phase 2
Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT01875250: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01875250 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01875250, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
Background: \- Enzalutamide is a well tolerated hormone therapy that is used to treat advanced prostate cancer. It is given to help kill cancer cells and limit cancer cell growth. A new possible way of treating prostate cancer is using a therapeutic cancer vaccine (immune stimulating therapy) that may help activate the immune system against the cancer. The immune stimulating vaccine will help white blood cells recognize and kill the cancer cells throughout the body. This vaccine therapy has been tested in hundreds of patients and is very well tolerated. Researchers want to see whether this vaccine, given with enzalutamide, is more effective at treating advanced prostate cancer than enzalutamide alone. Objectives: \- To compare the safety and effectiveness of enzalutamide with and without vaccine therapy for advanced prostate cancer. Key Eligibility: * Men at least 18 years of age who have advanced castration sensitive prostate cancer. * Patients must have testosterone within the normal range * No evidence of metastatic prostate cancer on computed tomography (CT) or Bone scan * No history of autoimmune diseases * No previous immunotherapy within 3 years Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies will be used to monitor the cancer before treatment. * Participants will be separated into two groups. One group will have enzalutamide and the study vaccine. The other group will have enzalutamide alone. * All participants will take enzalutamide once a day. They will take the drug for 3 months. This form of intermittent therapy is common in this population of patients. * The vaccine group of participants will receive the new study vaccine. They will have a single injection on the first day of the first study cycle. There will be regular booster injections afterward. There will be one injection during the third week of treatment, and one in the fifth week. The vaccine will
Interventions
- BIOLOGICAL PROSTVAC-F (Fowlpox)/TRICOM
- BIOLOGICAL PROSTVAC-V (Vaccinia)/TRICOM
- DRUG Enzalutamide (Xtandi)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2013-07-22 |
| Est. Completion | 2020-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01875250
The ClinicalTrials.gov registry entry for NCT01875250 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PROSTVAC-F (Fowlpox)/TRICOM is the first listed.
NCT01875250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01875250 about?
NCT01875250 is a clinical study titled "Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer". Background: \- Enzalutamide is a well tolerated hormone therapy that is used to treat advanced prostate cancer. It is given to help kill cancer cells and limit cancer cell growth. A new possible way of treating prostate cancer is using a therapeutic cancer vaccine (immune stimulating therapy) that ...
What is the current status of trial NCT01875250?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2013-07-22. Estimated completion is 2020-02-28.
What interventions are being tested in trial NCT01875250?
The interventions under investigation include: PROSTVAC-F (Fowlpox)/TRICOM (BIOLOGICAL), PROSTVAC-V (Vaccinia)/TRICOM (BIOLOGICAL), Enzalutamide (Xtandi) (DRUG).
Who is sponsoring clinical trial NCT01875250?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.